HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Novel analogue of colchicine induces selective pro-death autophagy and necrosis in human cancer cells.

Abstract
Colchicine, a natural product of Colchicum autumnae currently used for gout treatment, is a tubulin targeting compound which inhibits microtubule formation by targeting fast dividing cells. This tubulin-targeting property has lead researchers to investigate the potential of colchicine and analogs as possible cancer therapies. One major study conducted on an analogue of allocolchicine, ZD 6126, was halted in phase 2 clinical trials due to severe cardio-toxicity associated with treatment. This study involves the development and testing of novel allocolchicine analogues that hold non-toxic anti-cancer properties. Currently we have synthesized and evaluated the anti-cancer activities of two analogues; N-acetyl-O-methylcolchinol (NSC 51046 or NCME), which is structurally similar to ZD 6126, and (S)-3,8,9,10-tetramethoxyallocolchicine (Green 1), which is a novel derivative of allocolchicine that is isomeric in the A ring. NSC 51046 was found to be non-selective as it induced apoptosis in both BxPC-3 and PANC-1 pancreatic cancer cells and in normal human fibroblasts. Interestingly, we found that Green 1 was able to modestly induce pro-death autophagy in these pancreatic cancer cells and E6-1 leukemia cells but not in normal human fibroblasts. Unlike colchicine and NSC 51046, Green 1 does not appear to affect tubulin polymerization indicating that it has a different molecular target. Green 1 also caused increased reactive oxygen species (ROS) production in mitochondria isolated from pancreatic cancer cells. Furthermore, in vivo studies revealed that Green 1 was well tolerated in mice. Our findings suggest that a small change in the structure of colchicine has apparently changed the mechanism of action and lead to improved selectivity. This may lead to better selective treatments in cancer therapy.
AuthorsKristen Larocque, Pamela Ovadje, Sinisa Djurdjevic, Mariam Mehdi, James Green, Siyaram Pandey
JournalPloS one (PLoS One) Vol. 9 Issue 1 Pg. e87064 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID24466327 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 3,8,9,10-tetramethoxyallocolchicine
  • Antineoplastic Agents
  • NSC 51046
  • Reactive Oxygen Species
  • Tubulin
  • allocolchicine
  • Colchicine
Topics
  • Animals
  • Antineoplastic Agents (chemistry, pharmacology)
  • Autophagy (drug effects)
  • Blotting, Western
  • Cell Proliferation (drug effects)
  • Cells, Cultured
  • Colchicine (analogs & derivatives, chemistry, pharmacology)
  • Fibroblasts (cytology, drug effects, metabolism)
  • Humans
  • Leukemia, T-Cell (drug therapy, metabolism, pathology)
  • Male
  • Mice
  • Mice, Nude
  • Microtubules (drug effects, metabolism)
  • Mitochondria (drug effects, metabolism)
  • Necrosis
  • Pancreatic Neoplasms (drug therapy, metabolism, pathology)
  • Reactive Oxygen Species (metabolism)
  • Tubulin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: